Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors from the central nervous technique, conolidine modulates alternate molecular targets. A Science Advances review discovered that conolidine interacts Together with the atypical chemokine receptor ACKR3/CXCR7